 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Truist Financial Corp trimmed its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT  Free Report) by 68.7% during the 2nd quarter, according to its most recent Form 13F filing with...

Truist Financial Corp Cuts Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT  Get Free Report) have been assigned a consensus recommendation of Moderate Buy from the seven research firms that are...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Corcept Therapeutics management to meet with Piper Sandler

This is a signal that CORT's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Corcept Therapeutics (CORT, $24.91) RSI Indicator left the oversold zone on November 09, 2023

Corcept Therapeutics upgraded to Buy from Hold at Truist

Corcept Therapeutics Incorporated (NASDAQ:CORT  Free Report)  Equities researchers at HC Wainwright dropped their Q1 2024 earnings per share estimates for Corcept Therapeutics in a...

Q1 2024 EPS Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT) Reduced by Analyst

Granite Investment Partners LLC lessened its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT  Free Report) by 0.3% in the 2nd quarter, HoldingsChannel.com reports. The firm owned...

Granite Investment Partners LLC Has $17.63 Million Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT  Get Free Report) Director Daniel N. Swisher, Jr. sold 2,200 shares of the businesss stock in a transaction that occurred on Wednesday...

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares of Stock

Insider Sell: Chief Accounting Officer Joseph Lyon Sells 5,000 Shares of Corcept Therapeutics Inc

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Watchers	2,775
52-Wk Low	$17.86
52-Wk High	$34.28

Market Cap	$2.75B
Volume (M)	374,483.00
52-Wk High	$34.28
52-Wk Low	$17.86

Current Price	$25.56
Prev Close	$25.45
Open	$25.61
Dividend Yield	0.00%
50-Day Moving Average	$27.47
Beta	0.70
Avg. Volume	618,413.50
PE Ratio	31.44

52-Week High	$34.28
52-Week Low	$17.86
Market Capitalization	$2.75B
EPS	$0.8094
Price to Book	5.68
Revenue Per Employee	$1.51M
Enterprise Value/EBITDA	26.56

CORT Corcept Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals